巴他必利（BMY-25801）：一种用于预防癌症化疗引起呕吐的新型5-羟色胺3受体拮抗剂。 - Suppr | 超能文献

Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.

作者信息

Smaldone L, Plezia P, Alberts D, Aapro M, Sartiano G, Dorn M, Brady M, Comerski C, Schwartz S E, Fairchild C

机构信息

Bristol-Myers Squibb, Pharmaceutical Research Institute, Wallingford, CT 06492-7660.

出版信息

Cancer Treat Rev. 1990 Sep;17(2-3):319-27. doi: 10.1016/0305-7372(90)90064-m.

DOI:10.1016/0305-7372(90)90064-m

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.巴他必利（BMY-25801）：一种用于预防癌症化疗引起呕吐的新型5-羟色胺3受体拮抗剂。

Cancer Treat Rev. 1990 Sep;17(2-3):319-27. doi: 10.1016/0305-7372(90)90064-m.

2

Optimal control of acute cisplatin-induced emesis.急性顺铂所致呕吐的优化控制

Oncology. 1996 Jun;53 Suppl 1:56-64. doi: 10.1159/000227642.

3

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.20世纪90年代化疗引起的呕吐的治疗：5-羟色胺3受体拮抗剂的影响。

Support Care Cancer. 1994 Sep;2(5):286-92. doi: 10.1007/BF00365579.

4

A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.一项随机、双盲研究，比较接受中度致吐性化疗的患者中六种剂量的巴他必利（BMY-25801）与甲泼尼龙的疗效。

Ann Oncol. 1991 Oct;2(9):681-6. doi: 10.1093/oxfordjournals.annonc.a058049.

5

Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis.甲氧氯普胺和巴氯必利预防顺铂所致呕吐的双盲随机交叉研究

Cancer Chemother Pharmacol. 1991;28(3):226-7. doi: 10.1007/BF00685516.

6

A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.一份关于在严重呕吐情况下，将5-羟色胺3受体拮抗剂托烷司琼（呕必停）与地塞米松和胃复安的标准止吐方案用于顺铂治疗患者的比较报告。

Semin Oncol. 1994 Oct;21(5 Suppl 9):3-6.

7

Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.口服5-羟色胺3受体拮抗剂与小剂量口服胃复安加肌肉注射地塞米松预防接受大剂量顺铂治疗的头颈癌患者迟发性呕吐的比较。

Oncol Rep. 1998 Jan-Feb;5(1):273-80. doi: 10.3892/or.5.1.273.

8

Drug treatment of chemotherapy-induced delayed emesis.化疗引起的迟发性呕吐的药物治疗。

Drugs. 1996 Nov;52(5):639-48. doi: 10.2165/00003495-199652050-00002.

9

5HT3-antagonist receptors: their role in drug-induced emesis.5-羟色胺3拮抗剂受体：它们在药物性呕吐中的作用。

Nouv Rev Fr Hematol (1978). 1990;32(6):449-52.

10

BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.BMY - 25801，一种不具有D2 - 多巴胺受体拮抗剂特性的止吐药。

J Pharmacol Exp Ther. 1988 Mar;244(3):830-7.

引用本文的文献

1

The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.巴他必利及其代谢产物在肾功能不全受试者中的处置和蛋白结合情况。

Eur J Clin Pharmacol. 1993;45(1):59-63. doi: 10.1007/BF00315351.